$NCNA News

NuCana Appoints Ian Webster CFO, Effective Immediately

NuCana shares are trading lower. The company reported Q4 financial results.

NuCana shares are trading lower. The company reported Q4 financial results.

NuCana Q4 2025 EPS $0.00 and Revenue $0.00

European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

NuCana Appoints Theresa Bruce as Chief Operating Officer

NuCana Appoints Theresa Bruce COO, Effective Jan. 1

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

Nucana Reappoints Hugh S. Griffith As CEO, Effective Dec. 15

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Presents Data Showing Clinical Activity And Favorable Safety For NUC-7738 At ESMO Congress

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Announces China's National Intellectual Property Administration Has Granted A Composition Of Matter Patent For NUC-7738, Its Novel Anti-Cancer Agent

Reported Saturday, NuCana Highlights Synergy Between NUC-7738 And PD-1 Inhibitors In RCC Organoids, Supporting Expansion Of NuTide:701 Clinical Study

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy